Navigation Links
Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
Date:11/10/2009

er or more cost-effective treatment for physicians and patients than other FDA-approved products that currently are or will be on the market; that the Matrix clinical study program or other human clinical trials can be conducted and completed in an efficient and successful manner; that we can develop a DNA-based orthobiologics product portfolio; that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive; that FDA or other regulatory clearances or other certifications, or other commercialization efforts will be successful or will effectively enhance our businesses or their market value; that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population; or that third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2009 Cardium Therapeutics, Inc. All right
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cardium Announces $5.3 Million Registered Direct Offering
2. Cardium Completes $5.3 Million Registered Direct Offering
3. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
4. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
5. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
6. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
7. Cardium Reports on First Quarter 2008 Highlights and Financial Results
8. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
9. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
10. Cardium Launches New AWARE Clinical Study Website
11. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)...  Peter Walter was chosen as winner of the ... on how proteins are transported between cellular compartments and ... cells use to handle stress tied to the aggregation ... biochemistry at the University of California, San Francisco. His ... human diseases related to defective protein folding and transport. ...
(Date:3/27/2015)... SHANGHAI , March 27, 2015 ... a leading open-access R&D capability and technology platform ... device industries, announced today that an Investigational New ... monoclonal antibody for rheumatoid arthritis has been accepted ... Administration (CFDA).  In September 2012, ...
(Date:3/27/2015)... York (PRWEB) March 27, 2015 Governor ... 2015 application period for 43North - the world’s largest ... including a grand prize of $1 million, six $500,000 ... from around the world to compete for prizes that ... enterprises in the Western New York region. , ...
(Date:3/26/2015)... 2015 PRC Clinical, a Silicon-Valley based ... management and executive appointments effective immediately. , Mike Catelani ... and member of the Board of Directors. Daniel Head ... Sue Dowden will assume the position of Senior Director ... Operations Officer (COO), has been appointed to the position ...
Breaking Biology Technology:German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 3Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 2Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 3Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 4Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 5PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3
... , , , Customers can now conveniently ... on a short or long term basis to accelerate their ... (Nasdaq: SIAL ) today announced the launch of ... the pharmaceutical and biotechnology industry. The new Services Network provides ...
... Quality System and Facility Support Increased Capacity, Cost Reductions, Custom ... June 9 BioLife Solutions, Inc. (OTC Bulletin ... it has completed the construction and validation of its internal ... of its biopreservation media products made in Bothell for commercial ...
... ... Genomics, Inc. have identified a concise genetic signature found among a third of Parkinson,s disease ... found in the LRRK2 gene located on chromosome 12. The work was led by Elizabeth ... ...
Cached Biology Technology:Sigma-Aldrich Introduces New Services Network Complementing Its Life Sciences Product Portfolio 2BioLife Solutions Announces Validation and Start-Up of New Internal Manufacturing Facility for Serum-Free Cell and Tissue Biopreservation Media Products 2BioLife Solutions Announces Validation and Start-Up of New Internal Manufacturing Facility for Serum-Free Cell and Tissue Biopreservation Media Products 3Matrix Genomics, Elizabeth Corder, PhD - Gene Variation in the LRRK2 Gene and High Risk for Parkinson's Disease 2Matrix Genomics, Elizabeth Corder, PhD - Gene Variation in the LRRK2 Gene and High Risk for Parkinson's Disease 3
(Date:3/10/2015)... Utah , March 10, 2015   Tute ... interpretation, has been selected by next-generation sequencing company ... of whole exome and targeted gene panel interpretation. ... provider, has adopted the most current technologies to support ... genetic research. The company offers two types of exome ...
(Date:3/5/2015)... In Brazil , cloud computing ... these solutions and 42 percent planning to invest in them ... percent of the companies will be investing in these solutions ... companies in the region are currently opting for the private ... command significant attention in the coming years. This trend is ...
(Date:3/3/2015)... March 3, 2015 Cryoport, Inc. ... advanced cryogenic logistics solutions for the life ... cells, cell lines, clinical research organizations, vaccine ... announced the expansion of its relationship with ... ("Fred Hutch") Clinical Research Division with the ...
Breaking Biology News(10 mins):PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... Barbara, Calif.) Coastal marine ecosystems are at risk worldwide ... UC Santa Barbara who have recently published a study in ... performed the first integrated analysis of all coastal areas of ... must address a litany of impacts from human activities, from ...
... publish The HUGO Journal in cooperation with the ... Genomic Medicine, The HUGO Journal has a new ... of HUGO will receive free access to the journal online ... The HUGO Journal will focus on discoveries ...
... PHILADELPHIAThe Academy of Natural Sciences announced today that its ... member of the prestigious Biodiversity Heritage Library. The BHL ... botanical libraries and research institutions worldwide dedicated to digitizing ... it and to make it more widely available. Scanning ...
Cached Biology News:New study ranks 'hotspots' of human impact on coastal areas 2Academy Library accepted to prestigious Biodiversity Heritage Library 2
... Sensitivity Freezing Point Osmometer for 10 L sample. Ideal for small volume applications, including pediatric, neonatal, ... Ready to run in less than 3 minutes after turn-on. ... ... ...
X-Gal, 100 mg. 5-Bromo-4-chloro-3-indolyl-b-d-galactoside.Histochemical substrate for b-galactosidase, used in blue/white screening.Store at -20 C. Protect from moisture. Category: Nucleotides & Enzy...
Mouse/Rat WNK1 Affinity Purified Polyclonal Ab...
... Removal of excess dye terminators, template ... from the true sequencing products have proved ... This product is designed to work with ... BigDyeTM and DYEnamicTM ET. The unique uniformity ...
Biology Products: